Invivyd stock rises after FDA nod to start trial of COVID preventing therapy VYD222
Grandbrothers
- The U.S. Food and Drug Administration (FDA) cleared Invivyd's (NASDAQ:IVVD) investigational new drug application seeking to start a trial of VYD222 to prevent COVID-19, in vulnerable populations, such as immunocompromised people
- VYD222, which is a monoclonal antibody (mAb) candidate, is currently being evaluated in an ongoing phase 1 trial in healthy adults in Australia.
- "For the millions of immunocompromised people around the world who may not generate adequate protection from SARS-CoV-2 vaccines, there is an urgent need for new therapeutics that provide the rapid, passive immunity that results from the direct delivery of mAbs," said Invivyd's Chief Medical Officer Pete Schmidt.
- IVVD +3.84% to $1.12 premarket April 25